Proposed Collection; Comment Request; Generic Clearance To Conduct Voluntary Customer/Partner Surveys, 19673-19674 [2012-7831]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 63 / Monday, April 2, 2012 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0001]
Pediatric Advisory Committee; Notice
of Meeting
AGENCY:
Food and Drug Administration,
HHS.
mstockstill on DSK4VPTVN1PROD with NOTICES
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Pediatric
Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on May 7, 2012, from 8 a.m. to 5:30
p.m. and May 8, 2012, from 8:30 a.m. to
11:30 a.m.
Location: Hilton Rockville Executive
Meeting Center, 1750 Rockville Pike,
Rockville, MD 20852.
Contact Person: Walter Ellenberg,
Office of Pediatric Therapeutics, Office
of the Commissioner, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, rm. 5154, Silver Spring,
MD 20993, 301–796–0885, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), and follow the
prompts to the desired center or product
area. Please call the Information Line for
up-to-date information on this meeting.
A notice in the Federal Register about
last minute modifications that impact a
previously announced advisory
committee meeting cannot always be
published quickly enough to provide
timely notice. Therefore, you should
always check the Agency’s Web site and
call the appropriate advisory committee
hot line/phone line to learn about
possible modifications before coming to
the meeting.
Agenda: On May 7, 2012, the
Pediatric Advisory Committee will meet
to discuss pediatric-focused safety
reviews, as mandated by the Best
Pharmaceuticals for Children Act and
the Pediatric Research Equity Act, for
Differin Lotion (adapalene), Dulera
Inhalation Aerosol (mometasone furoate
and formotorol fumarate), MultiHance
Injection (gadobenate dimeglumine),
Nasonex (mometasone furoate
monohydrate), Natazia (estradiol
valerate and estradiol valerate/
dienogest), Omnaris Nasal Spray
(ciclesonide), Protonix (pantoprazole),
VerDate Mar<15>2010
17:42 Mar 30, 2012
Jkt 226001
Tamiflu (oseltamivir phosphate),
Taxotere (docetaxel) and Viread
(tenofovir disoproxil fumarate). The
committee will also receive an
Informational Update on FDA’s KidNet
pilot study.
On May 8, 2012, the Pediatric
Advisory Committee will meet
regarding the pediatric-focused safety
reviews, as mandated by the Pediatric
Research Equity Act, for Gardasil
Human Papillomavirus Quadrivalent
(Types 6, 11, 16, 18) Vaccine,
Recombinant, Isopto Carpine
(pilocarpine hydrochloride), Menveo
Meningococcal (Group A,C,Y, and W–
135) Oligosaccharide Diphtheria
CRM197 Conjugate Vaccine, Zylet
(loteprednol etabonate and tobramycin)
and Zymaxid (gatifloxacin).
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before April 30, 2012. Oral
presentations from the public will be
scheduled between approximately 11:30
a.m. and 12:30 p.m. on May 7, 2012.
Those individuals interested in making
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before April 20, 2012. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by April 23, 2012.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
19673
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Walter
Ellenberg at least 7 days in advance of
the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: March 23, 2012.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2012–7765 Filed 3–30–12; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment
Request; Generic Clearance To
Conduct Voluntary Customer/Partner
Surveys
In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995 to
provide opportunity for public comment
on proposed data collection projects, the
National Library of Medicine (NLM), the
National Institutes of Health (NIH) will
publish periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
Proposed Collection: Title: Generic
Clearance to Conduct Voluntary
Customer/Partner Surveys; Type of
Information Collection Request:
Extension of currently approved
collection [OMB No. 0925–0476,
expiration date 06/30/2012], Form
Number: NA; Need and Use of
Information Collection:: Executive
Order 12962 directed agencies that
provide significant services directly to
the public to survey customers to
determine the kind and quality of
services they want and their level of
satisfaction with existing services.
Additionally, since 1994, the NLM has
been a ‘‘Federal Reinvention
Laboratory’’ with a goal of improving its
methods of delivering information to the
public. An essential strategy in
SUMMARY:
E:\FR\FM\02APN1.SGM
02APN1
19674
Federal Register / Vol. 77, No. 63 / Monday, April 2, 2012 / Notices
accomplishing reinvention goals is the
ability to periodically receive input and
feedback from customers about the
design and quality of the services they
receive.
The NLM provides significant
services directly to the public including
health providers, researchers,
universities, other federal agencies, state
and local governments, and to others
through a range of mechanisms,
including publications, technical
assistance, and Web sites. These
services are primarily focused on health
and medical information dissemination
activities. The purpose of this
submission is to obtain OMB’s generic
approval to continue to conduct
satisfaction surveys of NLM’s
customers. The NLM will use the
information provided by individuals
and institutions to identify strengths
and weaknesses in current services and
to make improvements where feasible.
The ability to periodically survey NLM’s
customers is essential to continually
Estimated
number of
respondents
Types of respondents
Researchers, Physicians, Other Health Care Providers, Librarians, Students, General Public ...................................................................................
The annualized cost to respondents
for each year of the generic clearance is
estimated to be $20,670. There are no
Capital Costs, Operating Costs, and/or
Maintenance Costs to report.
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies should
address one or more of the following
points: (1) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) Evaluate the
accuracy of the agency’s estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and (4) Minimize the burden
of the collection of information on those
who are to respond, including the use
of appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: David Sharlip,
National Library of Medicine, Building
38A, Room B2N12, 8600 Rockville Pike,
Bethesda, MD 20894, or call non-toll
free number 301–402–9680 or Email
your request to sharlipd@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
mstockstill on DSK4VPTVN1PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
VerDate Mar<15>2010
17:42 Mar 30, 2012
Jkt 226001
[FR Doc. 2012–7831 Filed 3–30–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Small
Grants for Behavioral Research in Cancer
Control (R03).
Date: June 7, 2012.
Time: 8:30 a.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda, 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Ellen K Schwartz, EDD,
MBA, Scientific Review Officer,Special
Review & Logistics Branch, Division of
Extramural Activities, National Cancer
Frm 00065
Fmt 4703
Sfmt 9990
Estimated
number of
responses per
respondent
15,000
Dated: March 27, 2012.
David H. Sharlip,
NLM Project Clearance Liaison, National
Library of Medicine, National Institutes of
Health.
PO 00000
update and upgrade methods of
providing high quality service.
Frequency of Response: Annually or
biennially. Affected Public: Individuals
or households; businesses or other for
profit; state or local governments;
Federal agencies; non-profit institutions;
small businesses or organizations. Type
of Respondents: Organizations, medical
researchers, physicians and other health
care providers, librarians, students, and
the general public. The annual reporting
burden is as follows:
Average
burden hours
per response
1
Estimated total
annual burden
hours
requested
.150
2,250
Institute, NIH, 6116 Executive Boulevard
Room 8055B, Bethesda, MD 20892–8329,
301–594–1215, schwarel@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Innovative
Molecular Analysis Technologies for Cancer
(R21).
Date: June 26–27, 2012.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: Doubletree Hotel Bethesda, 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Jeffrey E. DeClue, Ph.D.,
Scientific Review Officer, Special Review
and Logistics Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
6116 Executive Boulevard Room 8059,
Bethesda, MD 20892–8329, 301–496–7904,
decluej@mail.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/sep/sep.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: March 27, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–7824 Filed 3–30–12; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\02APN1.SGM
02APN1
]]>Agencies
[Federal Register Volume 77, Number 63 (Monday, April 2, 2012)]
[Notices]
[Pages 19673-19674]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-7831]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment Request; Generic Clearance To
Conduct Voluntary Customer/Partner Surveys
SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995 to provide opportunity for public
comment on proposed data collection projects, the National Library of
Medicine (NLM), the National Institutes of Health (NIH) will publish
periodic summaries of proposed projects to be submitted to the Office
of Management and Budget (OMB) for review and approval.
Proposed Collection: Title: Generic Clearance to Conduct Voluntary
Customer/Partner Surveys; Type of Information Collection Request:
Extension of currently approved collection [OMB No. 0925-0476,
expiration date 06/30/2012], Form Number: NA; Need and Use of
Information Collection:: Executive Order 12962 directed agencies that
provide significant services directly to the public to survey customers
to determine the kind and quality of services they want and their level
of satisfaction with existing services. Additionally, since 1994, the
NLM has been a ``Federal Reinvention Laboratory'' with a goal of
improving its methods of delivering information to the public. An
essential strategy in
[[Page 19674]]
accomplishing reinvention goals is the ability to periodically receive
input and feedback from customers about the design and quality of the
services they receive.
The NLM provides significant services directly to the public
including health providers, researchers, universities, other federal
agencies, state and local governments, and to others through a range of
mechanisms, including publications, technical assistance, and Web
sites. These services are primarily focused on health and medical
information dissemination activities. The purpose of this submission is
to obtain OMB's generic approval to continue to conduct satisfaction
surveys of NLM's customers. The NLM will use the information provided
by individuals and institutions to identify strengths and weaknesses in
current services and to make improvements where feasible. The ability
to periodically survey NLM's customers is essential to continually
update and upgrade methods of providing high quality service. Frequency
of Response: Annually or biennially. Affected Public: Individuals or
households; businesses or other for profit; state or local governments;
Federal agencies; non-profit institutions; small businesses or
organizations. Type of Respondents: Organizations, medical researchers,
physicians and other health care providers, librarians, students, and
the general public. The annual reporting burden is as follows:
----------------------------------------------------------------------------------------------------------------
Estimated Estimated
Estimated number of Average total annual
Types of respondents number of responses per burden hours burden hours
respondents respondent per response requested
----------------------------------------------------------------------------------------------------------------
Researchers, Physicians, Other Health Care 15,000 1 .150 2,250
Providers, Librarians, Students, General Public
----------------------------------------------------------------------------------------------------------------
The annualized cost to respondents for each year of the generic
clearance is estimated to be $20,670. There are no Capital Costs,
Operating Costs, and/or Maintenance Costs to report.
Request for Comments: Written comments and/or suggestions from the
public and affected agencies should address one or more of the
following points: (1) Evaluate whether the proposed collection of
information is necessary for the proper performance of the function of
the agency, including whether the information will have practical
utility; (2) Evaluate the accuracy of the agency's estimate of the
burden of the proposed collection of information, including the
validity of the methodology and assumptions used; (3) Enhance the
quality, utility, and clarity of the information to be collected; and
(4) Minimize the burden of the collection of information on those who
are to respond, including the use of appropriate automated, electronic,
mechanical, or other technological collection techniques or other forms
of information technology.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the data collection plans and
instruments, contact: David Sharlip, National Library of Medicine,
Building 38A, Room B2N12, 8600 Rockville Pike, Bethesda, MD 20894, or
call non-toll free number 301-402-9680 or Email your request to
sharlipd@mail.nih.gov.
Comments Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 60 days
of the date of this publication.
Dated: March 27, 2012.
David H. Sharlip,
NLM Project Clearance Liaison, National Library of Medicine, National
Institutes of Health.
[FR Doc. 2012-7831 Filed 3-30-12; 8:45 am]
BILLING CODE 4140-01-P
